A preliminary gene expression analysis of public databases indicated that RHBDL2 expression significantly correlates with poor prognosis in breast cancer, pancreatic adenocarcinoma, clear cell kidney cancer, and low-grade glioma patients (Kmplot.com platform and TCGA PanCancer atlas, see Figure S7); this is consistent with previous data regarding RHBDL2 overexpression in basal-like breast carcinomas as compared to normal breast [45]. Here, RHBDL2 is linked to central nervous system cancer.